

**BRAINWEEK**

The

# **BRAIN & PAIN**

**Summit**

**APRIL 27-30**  
SCOTTSDALE, AZ

# **AGENDA**

This activity is jointly provided by Global Education Group and BRAINWeek.



**UMA**

**BRAINWEEK**

## THURSDAY, APRIL 27

1:00pm - 2:30pm	<b>Registration</b>	Trailblazer Registration
1:30pm - 2:30pm	<b>Welcome Hour/Snacks/Drinks</b> <i>Provided by the PAINWeek 2023 National Conference in Las Vegas</i>	Trailblazer Foyer
2:30pm - 3:30pm	<b>Diamond Headache Clinic: Epidemiology and Diagnosis</b> Merle Diamond, MD	Trailblazer B
3:30pm - 4:30pm	<b>Shadows and Light: How Grief Rewires the Brain</b> Michael Clark, MD	Trailblazer B
4:30pm - 5:30pm	<b>Diamond Headache Clinic: Prevention &amp; Treatment</b> Merle Diamond, MD	Trailblazer B
5:30pm - 5:45pm	<b>Break/Exhibits</b>	Trailblazer Foyer
5:45pm - 6:45pm	<b>Through the Looking Glass: Translating Psychedelic Research Into Clinical Paradigms</b> Dr. Eugene Vortsman, DO	Trailblazer B

## FRIDAY, APRIL 28

7:30am - 8:00am	<b>Continued Registration</b>	Trailblazer Registration
8:00am - 8:30am	<b>Breakfast</b> <i>Provided by the PAINWeek 2023 National Conference in Las Vegas</i>	Trailblazer A
8:30am - 9:30am	<b>Diamond Headache Clinic: Acute Treatment</b> Merle Diamond, MD	Trailblazer B
9:30am - 10:00am	<b>Break/Exhibits</b>	Trailblazer Foyer
10:00am - 11:00am	<b>Narcolepsy: What Lies Beneath</b> Alon Y. Avidan, MD, MPH	Trailblazer B
11:00am - 12:00pm	<b>Matilda's World: Sensible Pharmacology for Autism Spectrum Disorders</b> Jay Salpekar, MD	Trailblazer B
12:00pm - 12:30pm	<b>Break/Exhibits</b>	Trailblazer Foyer
12:30pm - 1:15pm	<b>Lunch</b> <i>Provided by the BRAINWeek 2023 National Conference in Las Vegas</i>	Trailblazer A
1:15pm - 2:15pm	<b>Things That Go Bump in the Night: Complex Nocturnal Behaviors</b> Alon Y. Avidan, MD, MPH	Trailblazer B
2:15pm - 3:15pm	<b>Turning a New Leaf: Examining Cannabinoids for Epilepsy Treatment</b> Jay Salpekar, MD	Trailblazer B
3:15pm - 3:30pm	<b>Break /Exhibits</b>	Trailblazer Foyer
3:30pm - 4:30pm	<b>Sleep as an Intervention for Neurological Conditions and Psychiatric Disorders</b> Fiona Barwick, PhD	Trailblazer B
4:30pm - 6:00pm	<b>Welcome Reception</b>	Trailblazer A

## SATURDAY, APRIL 29

8:00am - 8:30am	<b>Breakfast</b> <i>Provided by the BRAINWeek 2023 National Conference in Las Vegas</i>	Trailblazer A
8:30am - 9:30am	<b>The Devil is in the Details: Addressing Parkinson's Disease Psychosis</b> Gregory Pontone, MD	Trailblazer B
9:30am - 10:00am	<b>Exhibits/Break</b>	Trailblazer Foyer
10:00am - 11:00am	<b>Shuffling the Deck: Seizure Rescue Therapies</b> David Spencer, MD	Trailblazer B
11:00am - 12:00pm	<b>Joint Custody: Minding Osteoarthritis</b> Ramon Cuevas-Trisan, MD	Trailblazer B
12:00pm - 12:45pm	<b>Lunch</b> <i>Provided by the PAINWeek 2023 National Conference in Las Vegas</i>	Trailblazer A
12:45pm - 1:15pm	<b>Break/Exhibits</b>	Trailblazer Foyer
1:15pm - 2:15pm	<b>Off and On: Evaluating On-Demand Therapies for Parkinson's Disease</b> Gregory Pontone, MD	Trailblazer B
2:15pm - 3:15pm	<b>Where Is the Sandman? Addressing Sleep &amp; Chronic Pain</b> Fiona Barwick, PhD	Trailblazer B
3:15pm - 3:30pm	<b>Break /Exhibits</b>	Trailblazer Foyer
3:30pm - 4:30pm	<b>All That Jazz: Neurostimulation for Epilepsy</b> Sarah Kelley, MD	Trailblazer B

## SUNDAY, APRIL 30

8:00am - 9:00am	Sponsored Breakfast by Salix <b>Taking a Targeted Approach to Treating Opioid-Induced Constipation*</b> (*not certified for credit) Neel D. Mehta, MD	Trailblazer C
9:00am - 10:00am	<b>Breakfast of Champions: Ketamine Infusion for Chronic Pain and Depression</b> Kiran Patel, MD	Trailblazer B
10:00am - 10:15am	<b>Exhibits/Break</b>	Trailblazer Foyer
10:15am - 11:15am	<b>Walking on Spikes or Clouds?: DPNP Analgesics</b> Ramon Cuevas-Trisan, MD	Trailblazer B
11:15am	<b>Adjourn</b>	

### INSTRUCTIONS TO RECEIVE CREDIT

Please look for an email from [outcomes@globaleducationgroup.com](mailto:outcomes@globaleducationgroup.com) that will be sent to you following the conclusion of the BRAIN&PAIN Summit. The email will have your personalized link to complete the online conference evaluation form needed to receive your CE/CME certificate. Upon completion of this form, you will be able to download, print, and save your certificate immediately! Please make sure to check your junk mail folder, as this email may be tagged as spam.

## PROGRAM MATERIALS REQUIREMENTS

### Target Audience

The educational design of this activity addresses the needs of physicians, nurses, nurse practitioners, pharmacists, physician associates, psychologists, and allied HCPs who treat patients with various pain and/or neurological conditions.

### Statement of Need/Program Overview

The BRAIN & PAIN Summit is a 3 1/2-day conference presenting 18.0 accredited CE hours developed for clinicians treating pain and other CNS conditions. Topic areas include, but are not limited to, dementia, epilepsy, sleep, stroke, movement and neurodegenerative disorders, CNS and PNS related pain conditions.

### Educational Objectives

After completing this activity, the participant should be better able to:

1. Summarize the incidence rate and etiology of prevailing CNS disorders and chronic pain conditions
2. Describe reasons why differential diagnosis is imperative for CNS conditions and chronic pain disorders
3. Identify the social, economic, and health impacts of chronic pain and CNS disorders on both patients and caregivers
4. Recognize clinical pearls for varying disease states in the CNS and pain spaces
5. Recall approved and emerging therapies for CNS and pain disorders

### Faculty

- Alon Avidan, MD, MPH  
Director, UCLA Sleep Disorders Center
- David Spencer, MD  
Professor Of Neurology
- Eugene Vortsman, DO  
Clinical Director Of Addiction Medicine And Disease Management
- Fiona Barwick, PhD, DBSM  
Clinical Associate Professor
- Gregory M. Pontone, MD  
Neuropsychiatry, Associate Professor
- Jay Salpekar, MD, FANPA, FAES, DFAACAP  
Associate Professor Of Psychiatry And Neurology
- Kiran Patel, MD  
Interventional Pain Medicine Specialist
- Merle Diamond, MD  
President, Medical Director
- Michael R. Clark, MD, MPH, MBA  
Professor Of Psychiatry And Behavioral Sciences
- Ramon Cuevas-Trisan, MD  
Associate Chief Of Staff For Education & Research
- Sarah Kelley, MD  
Director, Pediatric Epilepsy Monitoring Unit

### Program Agenda

Link to agenda: <https://www.brainweek.org/brain-pain-summit-2023/>

### Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and BRAINWeek. Global is accredited by the ACCME to provide continuing medical education for physicians.

### Physician Credit Designation

Global Education Group designates this live activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.0 MOC point amount medical knowledge MOC in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 18.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

### Pharmacist Accreditation Statement



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

### Credit Designation

Global Education Group designates this continuing education activity for 18.0 contact hour(s) (1.80 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity.

### Psychology Accreditation Statement

Global Education Group (Global) is approved by the American Psychological Association (APA) to sponsor continuing education for psychologists. Global maintains responsibility for this program and its content.

This activity offers a maximum of 18 CE credits for psychologists. The instructional level of this activity is intermediate.

### Nurse Practitioner Continuing Education



This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and BRAINWeek. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 18.0 contact hour(s) (which includes 1.9 hour(s) of pharmacology).

### Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

### Instructions for Obtaining Credit

In order to receive credit, participants must complete each post-test for the activity they attended and complete the final evaluation. Participants must also score at least a 70% on the post-test and submit it. Statements of credit will be emailed within 4 to 6 weeks following the program.

### System Requirement

#### PC

- 1.4 GHz Intel Pentium 4 or faster processor (or equivalent) Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit) 512 MB of RAM (1 GB recommended)
- Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
- For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

**MAC**

- 1.83 GHz Intel Core Duo or faster processor  
512 MB of RAM (1 GB recommended)  
MAC OS X 10.12, 10.13 and 10.14
- Mozilla Firefox, Apple Safari, Google Chrome
- For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

**Fee Information & Refund/Cancellation Policy**

There is a fee for this educational activity.

Cancellation and Refund Policy  
Cancellations may be done online

Cancellations received online or in writing 14 or more days before the start of BRAIN & PAIN Summit will be refunded, less a \$50 service charge per attendee. No refund will be made less than 14 days prior to the start of the BRAIN & PAIN Summit

You may transfer your registration to BRAIN & PAIN Summit to a colleague or future meeting until 7 days prior to the start of the BRAIN & PAIN Summit with the payment of a \$50 service charge.

**Disclosures of Relevant Financial Relationships**

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

Alon Y. Avidan, MD, MPH	<b>Consulting Fee (e.g. Advisory Board):</b> IDORSIA; MERCK; TAKEDA; EISAI; HARMONY <b>Honoraria:</b> IDORSIA; MERCK; HARMONY <b>Speaker's Bureau:</b> MERCK; IDORSIA
Fiona Barwick, PhD	Nothing to disclose
Michael Clark, MD, MPH,, MBA	Nothing to disclose
Ramon Cuevas-Trisan, MD	<b>Consulting Fee (e.g., Advisory Board):</b> AbbVie, Hisamitsu <b>Speaker's Bureau:</b> AbbVie

Merle Diamond, MD	<b>Consulting Fee:</b> Lundbeck Pharmaceuticals, Amgen, Allergan, Abbvie, Assertio Therapeutics, Axsome Therapeutics, Biohaven Pharmaceuticals, Inc., BioDelivery Sciences International, Inc. (BDSI), Eli Lilly & Co., Impel Neuropharma, Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Satsuma Pharmaceuticals, Inc., Upsher-Smith Laboratories, Impel Neuro Pharma, Amneal Pharmaceuticals <b>Speakers Bureau:</b> Amgen, Axsome Therapeutics, Allergan, Abbvie, Assertio Therapeutics, Biohaven Pharmaceuticals, Inc., Eli Lilly & Co., Impel Neuropharma, Lundbeck Pharmaceuticals, Supernus Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Upsher-Smith Laboratories
Sarah Kelley, MD	Nothing to disclose
Kiran V. Patel, MD	Nothing to disclose
Gregory Pontone, MD	<b>Consulting Fee (e.g. Advisory board):</b> Acadia Pharmaceuticals Inc
Jay Salpekar, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Cerevel Therapeutics <b>Contracted Research:</b> Jazz Pharmaceuticals
David Spencer, MD	<b>Consulting Fee (e.g., Advisory Board):</b> NeuroPace, Inc <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> UCB; Neurona; NeuroPace
Eugene Vortsman, DO	Nothing to disclose

The planners and managers at Global Education Group have no relevant financial relationships to disclose. The planners and managers at BRAINWeek have no relevant financial relationships to disclose.

**Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and BRAINWeek do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

**SESSION TITLE      COURSE DESCRIPTION**

**Diamond  
Headache Clinic  
Migraine Track:  
Epidemiology  
and Diagnosis**

Migraine is a complex disorder of the nervous system that is recurrent and causes significant disability. In fact, it is the second most common cause of disability worldwide. Migraine attacks can occur unpredictably and are a major cause of missed time from work and other activities. The impact of migraine is staggering, affecting about 40 million Americans. Women have a significantly increased risk, and almost 1 in 5 are affected. Because migraine is often genetically transmitted, families may be impacted. This course will look at current diagnosis and secondary headache causes, cover what migraine is, and look at the common evolution of a migraine attack. Also to be discussed: the current classifications of migraine and what they mean in terms of disability and treatment, and the evolution of the understanding of migraine pathology and how it has introduced newer interventions for this patient population. Older theories will be covered, as well as what is understood today and the importance of CGRP, the risk factors for chronification of migraine, and how to take a headache history.  
UAN 0530-9999-23-034-L08-P

**Shadows and  
Light: How Grief  
Rewires the Brain**

Bereavement is the state of being deprived of something or someone, resulting in grief, an emotion which can draw one toward the something or someone missing. While the experience of social loss is universal, each person's individual grief is unique, and the path to returning to a life of satisfaction requires arduous work. This course will review the characteristics of grief, describe empirical studies validating models of grief, and define the construct of Prolonged Grief Disorder—newly listed in the Diagnostic and Statistical Manual of Mental Disorders, the American Psychiatric Association's handbook for mental health disorders. In addition, a summary of treatment trials for complicated grief, along with a framework for grief work, will be provided.  
UAN 0530-9999-23-035-L01-P

**Diamond  
Headache Clinic  
Migraine Track:  
Prevention  
Treatment**

Migraineurs need preventive treatment and learners will find out who and why as pharmacological treatments are discussed, along with neuromodulating devices, supplements, and lifestyle interventions. Migraine treatment has evolved dramatically in the past 5 years and, because of this, migraine patients have experienced better outcomes with fewer side effects. It is important to look at what prevention outcome goals are and how to can track them. Even though older treatments were fraught with tolerability issues and patient compliance, it is important to understand them. Older therapeutic agents, clinical data, and how to utilize the information will be addressed. The rating system for migraine prevention medicines, formulated by scientific data, will be explored. In the past several years there have been changes to preventative migraine treatments, including botulinum toxin for chronic migraine and the advent of monoclonal antibodies to CGRP and GPANTS.  
UAN 0530-9999-23-036-L08-P

**Through the  
Looking Glass:  
Translating  
Psychedelic  
Research Into  
Clinical Paradigms**

Embark on a journey to uncover the cultural, scientific, and political history of psychedelics. This course will delve into their early use by indigenous natives to the modern resurgence in use among scholars. What are the basic mechanisms behind the profound effects of these substances on the human brain and psyche? It's important to understand as much as possible as psychedelic medicine continues to gain mainstream acceptance. History is being made! Join us on this exciting expedition as we explore the new frontier of psychedelic medicine and its potential to transform our understanding of mental health and wellbeing.  
UAN 0530-9999-23-037-L08-P

**Diamond  
Headache Clinic  
Migraine Track:  
Acute Treatment**

This portion of the Migraine Track will dive into acute treatment options for patients struggling with migraine attacks. The course will review traditional tools and their most appropriate application for acute migraine attack management, and explore newer options for treatment, including oral, injectable, infused, and even nonpharmacologic tools available for patients in need of care. After reviewing efficacy and tolerability data, literature surrounding patient preference, and organizational position statements in headache treatment, best practices will be explored, including how to avoid common missteps that can lead to unintended consequences—medication overuse headaches, poor therapeutic outcomes, and even dependence issues with medications. The session will offer actionable choices a prescriber can utilize to best drive the strongest possible patient focused clinical outcomes when treating acute migraine attacks.  
UAN 0530-9999-23-038-L08-P

**SESSION TITLE      COURSE DESCRIPTION**

**Narcolepsy: What Lies Beneath**

Narcolepsy is a chronic neurological condition characterized by pervasive, excessive daytime sleepiness, as well as the abnormal intrusion of rapid eye movement sleep into wakefulness. Narcolepsy type I, or hypocretin deficiency syndrome, also includes cataplexy, where there is a sudden loss of skeletal muscle tone during wakefulness, and is often triggered by a strong emotion, such as laughter, surprise, or anger. Other symptoms of narcolepsy include fragmented or disturbed nighttime sleep, sleep paralysis, and hallucinations, either when falling asleep (hypnagogic) or when waking up (hypnopompic). The evaluation of people with suspected narcolepsy requires meticulous clinical history taking, validating the patient's sleep duration and regularity, and assessment of patients for conditions that could also present with hypersomnia such as insufficient sleep and delayed sleep phase disorder, depression, and obstructive sleep apnea. Management of people for narcolepsy includes lifestyle modification, short and strategic shift power naps, as well as a variety of pharmacologic agents to improve daytime sleepiness, episodes of cataplexy, and sleep fragmentation at night. The lecture will review all aspects of narcolepsy, defining its unique features, differential diagnosis, and strategies for evaluation, management, and patient advocacy.  
UAN 0530-9999-23-039-L01-P

**Matilda's World: Sensible Pharmacology for Autism Spectrum Disorders**

As mental health conditions associated with developmental disabilities become better identified, clinicians are often challenged by how to diagnose and treat them. Symptoms presentations can vary in the context of autism spectrum disorders. Additionally, the evidence base for treatment, both pharmacologic and nonpharmacologic, is not as well developed for those with developmental disabilities. This session will discuss theoretical underpinnings for co-occurring conditions and outline a treatment approach that allows integration with nonpharmacologic strategies. Psychopharmacologic approaches will be discussed in depth, as well as assessment strategies that may account for atypical symptom presentations of psychiatric conditions. The evidence base for pharmacologic treatments will be reviewed and practical strategies for management will be emphasized.  
UAN 0530-9999-23-040-L01-P

**Things That Go Bump in the Night: Complex Nocturnal Behaviors**

Complex nocturnal behaviors are some of the most fascinating sleep disorders in medical practice and often include a variety of conditions that require detective work. Parasomnias can include both simple and complex abnormal behaviors and are defined as abnormal sensory or behavioral phenomena that manifest during sleep-wake transition. Parasomnias are divided into those that occur during rapid eye movement (REM) sleep (including nightmares, isolated sleep paralysis, and REM sleep behavior disorder or RBD) and those occurring during nonrapid eye movement (NREM) sleep (such as sleepwalking, sleep terrors, and confusion on arousal. RBD often precedes the onset of neurodegenerative conditions, particularly  $\alpha$ -synucleinopathies, a group of neurodegenerative diseases characterized by abnormal accumulation of insoluble  $\alpha$ -synuclein in neurons and glial cells, comprising Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Other forms of complex behaviors include motor behaviors of sleep, such as rhythmic movements disorder, periodic leg movements of sleep, and bruxism. Sleep related epilepsy may resemble parasomnias but tend to be monomorphic and stereotyped. The lecture will provide insight into the differential diagnosis using video examples covering the unique features of the key parasomnias, their unique features, and management strategies.  
UAN 0530-9999-23-041-L01-P

**Turning a New Leaf: Examining Cannabinoids for Epilepsy Treatment**

Cannabinoids are varied in terms of products available and have multiple roles in the central nervous system. During this session, an updated overview of the endocannabinoid system and potential targets of therapeutic agents will be provided. Epilepsy is a common illness that has proven to improve with use of cannabinoids. Treatment approaches are challenging given the lack of available data and the uncertain quality of products. However, the therapeutic potential of these agents for epilepsy and in other conditions is vast and will be explored during this section.  
UAN 0530-9999-23-042-L01-P

**Sleep As an Intervention for Neurological Conditions and Psychiatric Disorders**

How can you help your patients sleep better, especially those who are reporting poor sleep in the context of co-occurring neurological and psychiatric conditions? This session gives you evidence-based recommendations for improving your patients' sleep, along with biological reasons that help you motivate your patients to use the strategies you recommend.  
UAN 0530-9999-23-043-L01-P

**SESSION TITLE      COURSE DESCRIPTION**

**The Devil Is in the Details: Addressing Parkinson's Disease Psychosis**

The spectrum of psychotic symptoms in Parkinson's disease may include disordered thinking, hallucinations—auditory, visual, olfactory, gustatory, tactile—delusions, and/or agitation. According to estimates from the Parkinson's Foundation Prevalence Project, 1.2 million people in the United States will be living with PD by the year 2030. This course will provide a summary of symptoms, along with strategies for efficient differential diagnosis and detection. Best-evidence treatment strategies will be outlined and discussed.  
UAN 0530-9999-23-044-L01-P

**Shuffling the Deck: Seizure Rescue Therapies**

Acute repetitive seizures (cluster seizures) and prolonged seizures are common in both childhood and adult epilepsy, and can be life threatening. This session will identify those at greatest risk for prolonged or repetitive seizures and review updates on treatment options. That information will be applied to cases, and practical rescue plans for patients will be discussed.  
UAN 0530-9999-23-045-L01-P

**Joint Custody: Minding Osteoarthritis**

Osteoarthritis (OA) pain complaints are among the most common encountered by a clinician in an ambulatory care practice. Many clinicians, however, lack up-to-date knowledge about proper staged management of this condition. This course will cover concepts of evaluation, including appropriate and directed history and basic exam and imaging findings that should be appraised when patients present with joint pain. We will discuss proven and unproven commonly accepted management methods for pain in OA and review the medical literature related to various therapies, both conservative and interventional, for its management. Also to be reviewed: evidence and indications for newer OA pain management therapies including regenerative injection therapy approaches.  
UAN 0530-9999-23-046-L08-P

**Off and On: Evaluating On-Demand Therapies for Parkinson's Disease**

Parkinson's disease is diagnosed in about 60,000 Americans each year; over 10 million people worldwide live with it. This session will describe the most common motor complications in Parkinson's disease. Factors that contribute to the emergence of on-off fluctuations will be reviewed, along with potential therapies.  
UAN 0530-9999-23-047-L01-P

**Where is the Sandman? Addressing Sleep and Chronic Pain**

Most people who suffer from chronic pain report poor sleep. Understanding their relationship, including common pathways, can help practitioners target the biological systems that impact both sleep and pain. This session will explore the biology and behaviors in chronic pain and chronic insomnia, show how they overlap, and provide evidence based techniques to help patients improve insomnia and manage chronic pain more effectively.  
UAN 0530-9999-23-052-L08-P

**All That Jazz: Neurostimulation in Epilepsy**

Epilepsy is a common neurologic disorder that can greatly affect a person's health and well-being. While many patients can be successfully treated with medication, about a third of patients with epilepsy become refractory to medical treatment. When this happens, the next step is to consider nonmedication options. This course will look at diagnosis and treatment of patients with epilepsy with a special focus on next steps in the evaluation and management of patients with refractory epilepsy and the use of devices and neurostimulation in this population.  
UAN 0530-9999-23-048-L01-P

**Breakfast of Champions: Ketamine Infusion for Chronic Pain and Depression**

Ketamine was developed in 1962 as a less hallucinogenic and shorter acting anesthetic agent than phencyclidine. It was first used in humans in 1964. Since then, ketamine has been used for a variety of purposes, including the management of acute pain, chronic pain, and depression. The history of ketamine will be examined, and the current evidence available supporting its use in chronic pain and depression will be presented.  
UAN 0530-9999-23-049-L08-P

**Walking on Spikes or Clouds?: DPNP Analgesics**

Pain associated with diabetic peripheral neuropathy can be disabling and difficult to manage. Reported pain is on the rise. Avoidance—by preventing/delaying the onset of diabetes—whenever possible, is critical. Proven effective treatments only help some patients with the condition. Management recommendations have evolved over the last 10 years based on newer agents and more medical evidence showing efficacy of some agents and lack of efficacy of others, challenging traditional paradigms. Medical evidence will be presented for various pharmacotherapy options, exercise, and minimally invasive treatment options. The practical selection of management methods depends on various factors including other medical conditions, cost, and experience of the patient's provider.  
UAN 0530-9999-23-050-L08-P

**SUMMIT FACULTY INFO**



**Alon Y. Avidan MD, MPH**  
 Director, UCLA Sleep Disorders Center  
 Professor & Vice Chair, UCLA Department of Neurology  
 Past Chair, Faculty Executive Committee  
 David Geffen School of Medicine at UCLA  
 Department of Neurology  
 Los Angeles, CA  
 Consulting Fee: Idorsia, Merck, Takeda, Eisai, Harmony  
 Honoraria: Harmony, Idorsia, Merck  
 Speaker's Bureau: Merck, Idorsia



**Fiona Barwick PhD, DBSM**  
 Clinical Associate Professor  
 Psychiatry and Behavioral Sciences - Sleep Medicine  
 Stanford University School of Medicine  
 Stanford, CA  
 Nothing to disclose



**Ramon L. Cuevas-Trisan MD**  
 Associate Chief of Staff for Education & Research  
 VAMC West Palm Beach  
 West Palm Beach, FL  
 Consulting Fee: AbbVie, Hisamitsu  
 Speaker's Bureau: AbbVie



**Merle Diamond MD**  
 President  
 Medical Director  
 Diamond Headache Clinic  
 Chicago, IL  
 Consulting Fee: Allergan/AbbVie, Amgen, Assertio  
 Therapeutics, Axsome Therapeutics, BioDelivery  
 Sciences International (BDSI), Biohaven  
 Pharmaceuticals,  
 Eli Lilly & Co., Lundbeck Pharmaceuticals  
 Impel Neuropharma, Promius Pharma,  
 Supernus Pharmaceuticals, Teva  
 Pharmaceuticals Industries Ltd., Satsuma  
 Pharmaceuticals, Inc., Upsher-Smith  
 Laboratories, Impel Neuro Pharma, Amneal  
 Pharmaceuticals  
 Speakers Bureau: Allergan/AbbVie,  
 Amgen,  
 Assertio Therapeutics, Axsome Pharma,  
 Biohaven  
 Pharmaceuticals, Eli Lilly & Co., Impel  
 Neuropharma, Lundbeck Pharmaceuticals,  
 Neuropharma,  
 Supernus Pharmaceuticals, Teva  
 Pharmaceuticals Industries Ltd., Upsher-  
 Smith Laboratories



**Michael R. Clark MD, MPH, MBA**  
 Professor of Psychiatry and Behavioral Sciences  
 George Washington School of Medicine  
 and Health Sciences  
 Washington, DC  
 Nothing to disclose



**Sarah Kelley MD**  
 Director, Pediatric Epilepsy Monitoring Unit  
 Associate Professor of Neurology  
 Johns Hopkins University School of Medicine  
 Baltimore, MD  
 Nothing to disclose



**Kiran V. Patel MD**  
 Director of Pain Medicine  
 Lennox Hill Hospital  
 New York, NY  
 Nothing to disclose



**Gregory Pontone MD, MHS**  
 Director, Parkinson's Disease Neuropsychiatry  
 Clinic  
 Associate Professor of Psychiatry and  
 Behavioral Sciences  
 Johns Hopkins University School of Medicine  
 Baltimore, MD  
 Consulting Fee: ACADIA Pharmaceuticals, Inc.



**Jay Salpekar MD, FANPA, FAES, dDFAACAP**  
 Associate Professor of Psychiatry and Neurology  
 Johns Hopkins University School of Medicine  
 Baltimore, MD  
 Consulting Fee: Cerevel Therapeutics  
 Contracted Research: Jazz Pharmaceuticals



**David Spencer MD**  
 Director, Comprehensive Epilepsy Center  
 Professor of Neurology, School of Medicine  
 Oregon Health Sciences University School  
 of Medicine  
 Portland, OR  
 Consulting Fee: NeuroPace, Inc.  
 Contracted Research: UCB; Neurona;  
 NeuroPace



**Eugene Vortsman DO, FACEP**  
 Clinical Director of Addiction Medicine  
 and Disease Management  
 Northwell Health, Long Island Jewish Medical  
 Center  
 Queens, NY  
 Nothing to Disclose

## 1st Providers Choice



4980 N. Ironwood Drive, Apache Junction, AZ 85120  
(480)782-1116  
accounting@1stproviderschoice.com  
IMS - Fully Certified Pain Medicine Specific Electronic Health Records & Practice Management Software. IMS is one of the most power and robust software solutions in the marketplace. Stop by our booth and see why so many practices are moving to IMS.

## Burden of Pain



1216 Richfield Court, Woodridge, IL 60517  
630-430-8024  
jjoshi45@gmail.com  
Author of Burden of Pain ([www.burdenofpain.com](http://www.burdenofpain.com))

## Pfizer



66 Hudson Boulevard, New York, NY 10001  
brian.phillips@pfizer.com  
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines.

## International Pain Foundation



4980 N. Ironwood Drive, Apache Junction, AZ 85120  
480-760-1985  
info@internationalpain.org  
Nonprofit involved in research, education, awareness for chronic pain conditions affecting the physical, mental, spiritual aspects of the pain community globally.

## MEDEIA



7 w Figueroa St Santa Barbara, CA  
18004334609  
info@medeia.com  
Since its inception in 1992, Medeia Inc has been on the forefront in the manufacture and distribution of Neuro Diagnostic and Heart Rate Variability / ANS products. Medeia Inc specializes in the development of state of the art biometrical software and hardware products intended to monitor physiology for research and educational purposes.

We provide a full spectrum of Neuro Functional and NeuroFeedback instruments, complimenting both the research and educational spheres, because our expert software and hardware development is focused on the design and implementation of highly innovative, industry leading products designed to meet the needs of researchers, consumers, educational, corporate, fitness and professional services.

The company's current products have proven marketability and are valued by practitioners and researchers in a variety of health care and professions throughout the world.

Our focus and goal is to continually seek strategic alliances to develop cooperative products and concepts to bring to the market place.

### National Headache Foundation



820 N. ORLEANS, SUITE 201  
CHICAGO, IL 60610  
312-274-2650  
888-643-5552  
INFO@HEADACHES.ORG

The National Headache Foundation (NHF), a volunteer, nonprofit organization located in Chicago, Illinois, was established in 1970 by a group of physicians.

**Mission** To cure headache, and to end its pain and suffering.

**Vision** A world without headache

In support of our mission, the National Headache Foundation looks to achieve these key goals:

**Advocacy** Represent the headache sufferer in efforts with the public, insurance providers, and governmental agencies.

**Awareness** Increase public awareness regarding headache and its impact on the individual, their families, and society.

**Education** Serve as the premiere resource by providing information to patients, health care professionals, and the media.

**Research** Promote research into potential headache causes and treatment

### Salix Pharmaceuticals



400 Somerset Corp Blvd, Bridgewater, NJ 0887  
1-800-321-4576

Salixcommunications@salix.com

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm healthcare providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit [www.Salix.com](http://www.Salix.com) and connect with us on Twitter and LinkedIn.



# **PainWeek.** **2023**

The National Conference on  
Pain for Frontline Practitioners

**SEPTEMBER 5-8**  
at The Cosmopolitan of Las Vegas

# **SAVE \$200**

Register today using code **BPLV200**

# **BRAINWeek™** **2023**

**SEPTEMBER 6-8**  
at The Cosmopolitan of Las Vegas

